KR102231139B1 - 세르핀 융합 폴리펩타이드 및 이의 이용 방법 - Google Patents

세르핀 융합 폴리펩타이드 및 이의 이용 방법 Download PDF

Info

Publication number
KR102231139B1
KR102231139B1 KR1020207005907A KR20207005907A KR102231139B1 KR 102231139 B1 KR102231139 B1 KR 102231139B1 KR 1020207005907 A KR1020207005907 A KR 1020207005907A KR 20207005907 A KR20207005907 A KR 20207005907A KR 102231139 B1 KR102231139 B1 KR 102231139B1
Authority
KR
South Korea
Prior art keywords
leu
lys
val
thr
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207005907A
Other languages
English (en)
Korean (ko)
Other versions
KR20200027041A (ko
Inventor
브랜든 피. 익클먼
존 씨. 타이머
피터 엘. 응우이
그랜트 비. 건터
퀸 데브루
Original Assignee
인히브릭스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인히브릭스, 인크. filed Critical 인히브릭스, 인크.
Publication of KR20200027041A publication Critical patent/KR20200027041A/ko
Application granted granted Critical
Publication of KR102231139B1 publication Critical patent/KR102231139B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
KR1020207005907A 2011-06-28 2012-06-28 세르핀 융합 폴리펩타이드 및 이의 이용 방법 Active KR102231139B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161502055P 2011-06-28 2011-06-28
US61/502,055 2011-06-28
US201161570394P 2011-12-14 2011-12-14
US61/570,394 2011-12-14
US201161577204P 2011-12-19 2011-12-19
US61/577,204 2011-12-19
US201261638168P 2012-04-25 2012-04-25
US61/638,168 2012-04-25
PCT/US2012/044730 WO2013003641A2 (en) 2011-06-28 2012-06-28 Serpin fusion polypeptides and methods of use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147002346A Division KR102084944B1 (ko) 2011-06-28 2012-06-28 세르핀 융합 폴리펩타이드 및 이의 이용 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217007901A Division KR20210032558A (ko) 2011-06-28 2012-06-28 세르핀 융합 폴리펩타이드 및 이의 이용 방법

Publications (2)

Publication Number Publication Date
KR20200027041A KR20200027041A (ko) 2020-03-11
KR102231139B1 true KR102231139B1 (ko) 2021-03-24

Family

ID=47424806

Family Applications (6)

Application Number Title Priority Date Filing Date
KR1020207005907A Active KR102231139B1 (ko) 2011-06-28 2012-06-28 세르핀 융합 폴리펩타이드 및 이의 이용 방법
KR1020217007901A Ceased KR20210032558A (ko) 2011-06-28 2012-06-28 세르핀 융합 폴리펩타이드 및 이의 이용 방법
KR1020217043197A Ceased KR20220003656A (ko) 2011-06-28 2012-06-28 세르핀 융합 폴리펩타이드 및 이의 이용 방법
KR1020237024532A Active KR102756547B1 (ko) 2011-06-28 2012-06-28 세르핀 융합 폴리펩타이드 및 이의 이용 방법
KR1020257001261A Pending KR20250012200A (ko) 2011-06-28 2012-06-28 세르핀 융합 폴리펩타이드 및 이의 이용 방법
KR1020147002346A Active KR102084944B1 (ko) 2011-06-28 2012-06-28 세르핀 융합 폴리펩타이드 및 이의 이용 방법

Family Applications After (5)

Application Number Title Priority Date Filing Date
KR1020217007901A Ceased KR20210032558A (ko) 2011-06-28 2012-06-28 세르핀 융합 폴리펩타이드 및 이의 이용 방법
KR1020217043197A Ceased KR20220003656A (ko) 2011-06-28 2012-06-28 세르핀 융합 폴리펩타이드 및 이의 이용 방법
KR1020237024532A Active KR102756547B1 (ko) 2011-06-28 2012-06-28 세르핀 융합 폴리펩타이드 및 이의 이용 방법
KR1020257001261A Pending KR20250012200A (ko) 2011-06-28 2012-06-28 세르핀 융합 폴리펩타이드 및 이의 이용 방법
KR1020147002346A Active KR102084944B1 (ko) 2011-06-28 2012-06-28 세르핀 융합 폴리펩타이드 및 이의 이용 방법

Country Status (28)

Country Link
US (8) US8980266B2 (https=)
EP (2) EP3569243A1 (https=)
JP (5) JP2014523900A (https=)
KR (6) KR102231139B1 (https=)
CN (3) CN110066340B (https=)
AU (4) AU2012275287B2 (https=)
BR (1) BR112013033799A2 (https=)
CA (2) CA3132298A1 (https=)
CY (1) CY1122195T1 (https=)
DK (1) DK2726092T3 (https=)
ES (1) ES2746052T3 (https=)
HR (1) HRP20191652T1 (https=)
HU (1) HUE046156T2 (https=)
IL (3) IL276534B2 (https=)
IN (1) IN2013MN02441A (https=)
LT (1) LT2726092T (https=)
ME (1) ME03473B (https=)
MX (2) MX381183B (https=)
NZ (1) NZ744257A (https=)
PL (1) PL2726092T3 (https=)
PT (1) PT2726092T (https=)
RS (1) RS59368B1 (https=)
RU (4) RU2642310C2 (https=)
SG (2) SG10201601621PA (https=)
SI (1) SI2726092T1 (https=)
SM (1) SMT201900520T1 (https=)
UA (2) UA130601C2 (https=)
WO (1) WO2013003641A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012178102A2 (en) * 2011-06-24 2012-12-27 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
KR102231139B1 (ko) 2011-06-28 2021-03-24 인히브릭스, 인크. 세르핀 융합 폴리펩타이드 및 이의 이용 방법
AU2012275295B2 (en) * 2011-06-28 2016-11-10 Inhibrx, Lp WAP domain fusion polypeptides and methods of use thereof
CA2896951A1 (en) * 2012-01-10 2013-07-18 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
WO2013156054A1 (en) 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
EP2877589B1 (en) 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
KR101509020B1 (ko) * 2013-05-22 2015-04-14 (주)입디 알파 1 안티트립신 융합 분자에 대한 조성물, 방법 및 용도
EP3155117A4 (en) * 2014-06-11 2017-11-22 Beth Israel Deaconess Medical Center, Inc. Alpha1-antitrypsin compositions and methods of treating autoimmune diseases
TW201613981A (en) * 2014-07-23 2016-04-16 Inova Diagnostics Inc Compositions and methods for the diagnosis of rheumatoid arthritis
NZ769391A (en) * 2014-10-27 2024-12-20 Sanofi Aatd Inc Serpin fusion polypeptides and methods of use thereof
US20160130324A1 (en) * 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
US11422719B2 (en) 2016-09-15 2022-08-23 Pure Storage, Inc. Distributed file deletion and truncation
EP3600345A4 (en) * 2017-03-29 2021-01-06 Cornell University OXIDATION-RESISTANT AAT GENE THERAPY
CN118221546A (zh) 2017-07-27 2024-06-21 密歇根大学董事会 纤维蛋白溶酶原活化物抑制因子-1（pai-1）抑制剂和使用方法
CN109705211B (zh) 2017-10-26 2020-08-18 苏州复融生物技术有限公司 一种IgG1 Fc单体及其应用
AU2018374285B2 (en) 2017-12-01 2024-06-27 Csl Behring Llc Methods for reducing risk of onset of acute graft versus host disease after hematopoeitic cell transplantation
CA3117961A1 (en) * 2018-10-29 2020-05-07 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders
AU2020301529B2 (en) 2019-06-24 2026-03-26 Universität Stuttgart TNFR2 agonists with improved stability
CA3145702A1 (en) * 2019-08-01 2021-02-04 Philip A. Pemberton Oxidation-resistant serpins
CN114867865A (zh) * 2019-11-21 2022-08-05 密执安大学评议会 中性粒细胞弹性蛋白酶活性的多肽抑制剂及其用途
CN110964094B (zh) * 2019-12-20 2021-11-02 华中科技大学 人源白细胞蛋白酶抑制因子及其重组制备与应用
CN112341538A (zh) * 2020-10-27 2021-02-09 苏州复融生物技术有限公司 一种Fc单体多肽及其应用
CA3206022A1 (en) * 2021-01-26 2022-08-04 Traian Sulea Ace2-receptor ectodomain fusion molecules and uses thereof
GB202102258D0 (en) 2021-02-17 2021-03-31 Arecor Ltd Novel composition
WO2023122120A1 (en) * 2021-12-22 2023-06-29 The Regents Of The University Of California Compositionsand methods for wound healing
WO2023225513A1 (en) 2022-05-16 2023-11-23 Inhibrx, Inc. Effective dosage of recombinant serpin-fc fusion protein for use in a method of treating aat deficiency in a subject
CN115466323B (zh) * 2022-09-13 2025-07-01 宁波博睿瀚达生物科技有限公司 一种分离分泌性白细胞蛋白酶抑制因子的方法
EP4483951A1 (en) * 2023-06-30 2025-01-01 Université de Liège Single-domain antibody for inhibition of neutrophil elastase activity
WO2025083294A2 (en) 2024-02-29 2025-04-24 Ageronix SA Aat-fc fusion protein
WO2025219443A1 (en) 2024-04-19 2025-10-23 Uniqure Biopharma B.V. Nucleic acid for a1at regulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030040097A1 (en) * 1999-03-01 2003-02-27 Human Genome Sciences, Inc. Serpin polynucleotides, polypeptides, and antibodies

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7253264B1 (en) * 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
US5734014A (en) 1992-08-11 1998-03-31 Tsumura & Co. Elafin derivative
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
TW575567B (en) * 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6849605B1 (en) * 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
AU779612C (en) 1999-07-02 2005-12-15 Genentech Inc. Peptide compounds that bind HER2
JP2003515325A (ja) * 1999-12-01 2003-05-07 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４ジスルフィドコアドメイン含有（ｆｄｃｄ）ポリヌクレオチド、ポリペプチド、および抗体
EP2213743A1 (en) * 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
FR2814957B1 (fr) 2000-10-06 2002-12-20 Aventis Pasteur Composition vaccinale et procede de stabilisation
US20050101632A1 (en) * 2000-11-08 2005-05-12 Lyne Gagnon Method for the treatment of inflammation
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
US7083784B2 (en) * 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US7247704B2 (en) * 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
EP1366175B1 (en) * 2000-12-18 2008-01-23 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
AU2002335930B2 (en) 2001-03-09 2005-07-28 Morphosys Ag Serum albumin binding moieties
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US6797493B2 (en) 2001-10-01 2004-09-28 Lee-Hwei K. Sun Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1415664A1 (en) * 2002-10-30 2004-05-06 Switch Biotech Aktiengesellschaft Use of alpha 1-antichymotrypsin in combination with alpha-1-antitrypsin for treating/preventing diabetes associated or poorly healing arterial wounds
US7427595B1 (en) 2002-12-12 2008-09-23 Cornell Research Foundation, Inc. Use of proepithelin to promote wound repair and reduce inflammation
DE10303664A1 (de) * 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
ATE385806T1 (de) 2003-06-12 2008-03-15 Lilly Co Eli Fusionsproteine
US7850970B2 (en) * 2003-08-26 2010-12-14 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
ES2383300T3 (es) * 2003-11-13 2012-06-20 Hanmi Holdings Co., Ltd Fragmento Fc de IgG para un vehículo de fármacos y procedimiento para su preparación
EP1737499A4 (en) * 2004-03-09 2009-07-22 Arriva Pharmaceuticals Inc TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASE BY INHALATION OF LOW DOSES OF A PROTEASE HEMMER
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
EP2194064A1 (en) 2004-05-13 2010-06-09 Eli Lilly & Company FGF-21 fusion proteins
GEP20105110B (en) 2004-08-03 2010-11-10 Transtech Pharma Inc Rage fusion proteins and their use
AU2005334481A1 (en) 2004-08-11 2007-01-25 Trubion Pharmaceuticals, Inc. Binding domain fusion proteins
US7399746B2 (en) 2004-10-06 2008-07-15 Mcgill University Agents for wound healing
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
ES2971647T3 (es) * 2005-04-15 2024-06-06 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
CA2609262A1 (en) 2005-06-03 2006-12-07 Mochida Pharmaceutical Co., Ltd. Anti-cd14 antibody fusion protein
EP2083081A1 (en) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
WO2007021807A1 (en) 2005-08-12 2007-02-22 Schering Corporation Mcp1 fusions
ES2649983T3 (es) * 2005-11-23 2018-01-16 Acceleron Pharma, Inc. Antagonistas de activina-ActRIIa en su uso para promover el crecimiento óseo
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
CA2647246C (en) 2006-03-30 2015-06-23 Research Foundation Of City University Of New York Stimulation of neuron regeneration by secretory leukocyte protease inhibitor
GB0614780D0 (en) * 2006-07-25 2006-09-06 Ucb Sa Biological products
WO2008025747A1 (en) * 2006-08-28 2008-03-06 Ares Trading S.A. Process for the purification of fc-fusion proteins
US20110020269A1 (en) 2007-05-08 2011-01-27 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for modifying t cell immune responses and inflammation
ES2623925T3 (es) * 2007-05-30 2017-07-12 Postech Academy-Industry- Foundation Proteínas de fusión de inmunoglobulina
CA2688433A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
WO2009045508A1 (en) * 2007-10-02 2009-04-09 Research Foundation Of City University Of New York Novel protein transduction domains derived from secretory leukocyte protease inhibitor
AR064713A1 (es) 2007-12-28 2009-04-22 Consejo Nac Invest Cient Tec Proteina de fusion que se une a transglutaminasas , composiciones que la comprenden , micro- esferas que la comprenden, usos y metodos
EP2307456B1 (en) 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
MX2011000861A (es) * 2008-07-23 2011-06-21 Hanmi Holdings Co Ltd Un complejo polipeptidico que consiste en un polimero no-peptidil que posee tres terminaciones funcionales.
EP2318529B1 (en) 2008-08-04 2017-10-18 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
DK2786762T3 (da) 2008-12-19 2019-05-06 Macrogenics Inc Kovalente diabodies og anvendelser deraf
NZ595461A (en) 2009-04-10 2013-01-25 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
JP5727459B2 (ja) * 2009-04-22 2015-06-03 アルテオゼン， インクＡｌｔｅｏｇｅｎ， Ｉｎｃ 体内持続性を維持することにより体内半減期が増加したタンパク質またはペプチド融合体
SE533763C2 (sv) 2009-05-04 2010-12-28 Lars Hammar Upphängningsanordning
CN103002727B (zh) 2009-07-08 2016-04-27 密苏里大学管委会 利用传统大豆育种技术培育高油酸大豆的方法
LT2498799T (lt) 2009-11-13 2016-11-10 Five Prime Therapeutics, Inc. Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis
GB201003559D0 (en) 2010-03-03 2010-04-21 Proteo Biotech Ag Novel use of elafin
EP2588140A4 (en) 2010-06-30 2015-07-15 Univ Maryland DENTAL COMPOSITES COMPRISING AMORPHOUS CALCIUM PHOSPHATE NANOPARTICLES
ES2623912T3 (es) 2010-12-23 2017-07-12 Janssen Biotech, Inc. Mutantes FC de anticuerpo activo resistente a proteasa
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
EP2537864B1 (en) 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
WO2012178102A2 (en) 2011-06-24 2012-12-27 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
AU2012275295B2 (en) 2011-06-28 2016-11-10 Inhibrx, Lp WAP domain fusion polypeptides and methods of use thereof
KR102231139B1 (ko) 2011-06-28 2021-03-24 인히브릭스, 인크. 세르핀 융합 폴리펩타이드 및 이의 이용 방법
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
CN103930124B (zh) * 2011-07-01 2021-05-11 生物基因Ma公司 无精氨酸的tnfr：fc-融合多肽组合物及使用方法
CA2896951A1 (en) 2012-01-10 2013-07-18 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
HK1209034A1 (en) 2012-06-21 2016-03-24 Indiana University Research And Technology Corporation Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
KR20150030744A (ko) 2012-06-27 2015-03-20 에프. 호프만-라 로슈 아게 표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
PL2880170T3 (pl) 2012-08-02 2017-02-28 F.Hoffmann-La Roche Ag SPOSÓB WYTWARZANIA ROZPUSZCZALNEGO FcR JAKO FUZJI Fc Z OBOJĘTNYM REGIONEM Fc IMMUNOGLOBULINY I JEGO ZASTOSOWANIA
US9758807B2 (en) 2012-12-05 2017-09-12 SOLA Biosciences, LLC Protein expression enhancing polypeptides
CN203917563U (zh) 2014-03-27 2014-11-05 陈广煌 一种切角模具
EP3155117A4 (en) * 2014-06-11 2017-11-22 Beth Israel Deaconess Medical Center, Inc. Alpha1-antitrypsin compositions and methods of treating autoimmune diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030040097A1 (en) * 1999-03-01 2003-02-27 Human Genome Sciences, Inc. Serpin polynucleotides, polypeptides, and antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Chromatography A, Vol. 1216, pp.5849-5855 (2009.)*

Also Published As

Publication number Publication date
AU2021202131B2 (en) 2023-01-12
NZ744257A (en) 2022-10-28
UA130601C2 (uk) 2026-04-01
ES2746052T3 (es) 2020-03-04
KR102084944B1 (ko) 2020-04-17
EP2726092A4 (en) 2015-08-19
SMT201900520T1 (it) 2019-11-13
SG10201601621PA (en) 2016-04-28
US11827691B2 (en) 2023-11-28
EP2726092A2 (en) 2014-05-07
AU2019202904A1 (en) 2019-05-16
CY1122195T1 (el) 2020-11-25
IL276534A (en) 2020-09-30
LT2726092T (lt) 2019-10-10
CN103917563A (zh) 2014-07-09
US20200102371A1 (en) 2020-04-02
MX2013015323A (es) 2014-06-23
RU2020124172A (ru) 2022-01-21
KR20200027041A (ko) 2020-03-11
RU2642310C2 (ru) 2018-01-24
US20130011398A1 (en) 2013-01-10
SG10201811256QA (en) 2019-01-30
WO2013003641A3 (en) 2013-03-21
US20210024613A1 (en) 2021-01-28
IL276534B2 (en) 2025-11-01
AU2012275287A1 (en) 2014-01-16
CN110066340A (zh) 2019-07-30
AU2021202131A1 (en) 2021-05-06
CN110066340B (zh) 2024-06-25
KR20220003656A (ko) 2022-01-10
US10730929B2 (en) 2020-08-04
IN2013MN02441A (https=) 2015-06-12
CA2839619C (en) 2021-11-16
RS59368B1 (sr) 2019-11-29
US8980266B2 (en) 2015-03-17
AU2012275287B2 (en) 2017-10-05
RU2017145308A (ru) 2019-02-18
EP3569243A1 (en) 2019-11-20
JP2024138397A (ja) 2024-10-08
MX356517B (es) 2018-06-01
UA124083C2 (uk) 2021-07-21
KR102756547B1 (ko) 2025-01-21
CA3132298A1 (en) 2013-01-03
RU2728861C1 (ru) 2020-07-31
CA2839619A1 (en) 2013-01-03
RU2017145308A3 (https=) 2019-02-18
EP2726092B1 (en) 2019-06-19
US20180179264A1 (en) 2018-06-28
KR20140054000A (ko) 2014-05-08
DK2726092T3 (da) 2019-09-30
PT2726092T (pt) 2019-10-08
US10723785B2 (en) 2020-07-28
PL2726092T3 (pl) 2019-11-29
BR112013033799A2 (pt) 2017-02-14
US9920109B2 (en) 2018-03-20
HUE046156T2 (hu) 2020-02-28
JP2020078325A (ja) 2020-05-28
US20210002352A1 (en) 2021-01-07
RU2698655C2 (ru) 2019-08-28
RU2014102583A (ru) 2015-08-10
JP2022109968A (ja) 2022-07-28
JP2014523900A (ja) 2014-09-18
US20130330769A1 (en) 2013-12-12
HRP20191652T1 (hr) 2019-12-13
WO2013003641A2 (en) 2013-01-03
IL312872A (en) 2024-07-01
JP2018008956A (ja) 2018-01-18
SI2726092T1 (sl) 2019-11-29
KR20210032558A (ko) 2021-03-24
AU2017279724B2 (en) 2019-03-14
AU2019202904B2 (en) 2021-01-07
CN110551223A (zh) 2019-12-10
US20150147325A1 (en) 2015-05-28
KR20250012200A (ko) 2025-01-23
ME03473B (me) 2020-01-20
RU2727452C1 (ru) 2020-07-21
US11965017B2 (en) 2024-04-23
IL230209B (en) 2020-08-31
AU2017279724A1 (en) 2018-01-25
MX381183B (es) 2025-03-12
IL276534B1 (en) 2025-07-01
US20250011394A1 (en) 2025-01-09
JP6674604B2 (ja) 2020-04-01
NZ619023A (en) 2015-07-31
KR20230114318A (ko) 2023-08-01

Similar Documents

Publication Publication Date Title
KR102231139B1 (ko) 세르핀 융합 폴리펩타이드 및 이의 이용 방법
KR20240005109A (ko) 세르핀 융합 폴리펩티드 및 이의 사용 방법
RU2846432C2 (ru) Слитые серпиновые полипептиды и способы их применения
HK40017627A (en) Serpin fusion polypeptides and methods of use thereof
HK1197544B (en) Serpin fusion polypeptides and methods of use thereof
HK1197544A (en) Serpin fusion polypeptides and methods of use thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6